Titlebook: Antisense Therapeutics; Sudhir Agrawal Book 19961st edition Humana Press 1996

accessory

Continuous Infusion of Antisense Phosphorothioate Therapeutics,rone. Unfortunately, most patients relapse from initial remission. Nearly one-fifth of early relapses experience treatment-related deaths. In addition, patients refractory to Ara-C die within months. Hence, new therapeutic agents must be identified capable of enhanced remission rates, diminished tre

别炫耀

Protein Kinase-A Directed Antisense Therapy of Tumor Growth In Vivo,herapeutic agent. in principle, an antisense oligonucleotide targeted at a gene essential for neoplastic cell growth should interfere with only that gene’s expression, resulting in arrest of cancer cell growth.

放逐

aviator

Comparative Pharmacokinetics of Antisense Oligonucleotides,enetic disorders because of their ablhty to inhibit expression of a disease-associated gene in a sequence-specific manner. Gene expression is inhibited by hybrid ization of the oligonucleotide to sequences in the gene or the messenger RNA (mRNA) target by Watson-Crick base pairing. The first example

潜移默化

accomplishment

https://doi.org/10.1007/978-3-319-33927-6e (.). The principal cause for disassociation of IkB from NFis phosphorylation (.), but it may involve proteolysis of IkB (.) Several autoregulatory loops have been proposed for the involvement of NF-kB in the regulation of the inhibitor IkB. Furthermore, NF-kB has been shown to regulate the transcr

deforestation